年龄对白消安-美法仑联合自体造血干细胞移植与标准化疗在EURO-E.W.I.N.G. 99和Ewing 2008临床试验患者中安全性影响
在Euro-E.W.I.N.G.99和Ewing-2008试验的R2Loc和R2Pulm随机试验中,共243例接受VAI、205例接受BuMel。BuMel较VAI与更高的严重急性毒性风险相关,但按年龄组(<12岁、12-17岁、18-24岁、≥25岁)未观察到该超额风险存在显著异质性,提示BuMel在各年龄组可行。
要点
- BuMel较VAI与更高的严重急性毒性风险相关,尤其血液学、胃肠道、肝脏、肝窦阻塞综合征和感染。
- 无论何种治疗,严重血液学毒性和一般状况较差在年轻患者中更常见。
- 按年龄组未观察到BuMel较VAI的严重毒性超额风险存在显著异质性。
核心结论
- BuMel较VAI的超额急性毒性风险不随年龄显著变化,提示BuMel在各年龄组可行。
研究设计与样本
- 分析Euro-E.W.I.N.G.99和Ewing-2008试验中R2Loc和R2Pulm随机试验的患者,纳入局部高危或肺/胸膜转移者。
- 共243例接受VAI,205例接受BuMel;按随机治疗组(VAI vs BuMel)和年龄组(<12岁、12-17岁、18-24岁、≥25岁)分析严重毒性风险。
- 采用多变量logistic模型中的交互项评估按年龄组的治疗效应异质性。
主要发现
- BuMel较VAI与更高的严重急性毒性风险相关,尤其血液学、胃肠道、肝脏、肝窦阻塞综合征和感染。
- 无论何种治疗,严重血液学毒性和一般状况较差在年轻患者中显著更常见。
- 按年龄组未观察到BuMel较VAI的严重毒性超额风险存在显著异质性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Ewing sarcoma (ES), is a rare cancer affecting children, adolescents and adults. After VIDE (vincristine-ifosfamide-doxorobucin-etoposide) induction chemotherapy, Busulfan-Melphalan (BuMel) high-dose chemotherapy followed by autologous hematopoietic stem cells transplantation improved outcomes in unfavourable localized ES, but with more toxicities than conventional chemotherapy (VAI: Vincristine-dactinomycin-Ifosfamide). We evaluated whether the risk of acute toxicity associated with BuMel compared to VAI varied according to age in patients recruited in the R2Loc and R2Pulm randomised trials of the Euro-E.W.I.N.G.99 and Ewing-2008 trials. METHODS: We included patients with a localized high-risk disease, or pulmonary or pleural metastasis. We analysed the risk of severe toxicity according to randomised treatment group (VAI versus BuMel) and age group (<12 years, 12-17 years, 18-24 years, ≥25 years). We evaluated the heterogeneity of treatment effects by age group using interaction terms in logistic multivariable models. RESULTS: The analysis included 243 patients treated with VAI and 205 with BuMel. Overall, BuMel was associated with a higher risk of severe acute toxicity than VAI particularly haematological, gastrointestinal, liver, sinusoidal occlusive syndrome, and infections. Severe haematological toxicity and lower general condition were significantly more frequent in younger patients, whatever treatment. We did not observe any significant heterogeneity in terms of the excess risk of severe toxicities associated with BuMel compared to VAI according to age group. CONCLUSION: The excess of acute toxicity associated with BuMel compared to VAI does not vary significantly with age, suggesting the feasibility of BuMel across all age groups.
引用
- Choderlos de Laclos X, Risbourg S, Brennan B, et al. Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials. Eur J Cancer. 2024. PMID: 39032218. doi:10.1016/j.ejca.2024.114229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。